Contact Information
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Dean A. Lee
Biography
Dean Anthony Lee, MD, PhD, is a physician in the Division of Hematology and Oncology at Nationwide Children’s Hospital and director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children’s Hospital and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He is a professor of pediatrics at The Ohio State University College of Medicine and the DiMarco Family Endowed Chair in Cell Based Therapy. Dr. Lee earned his bachelor’s degree in natural sciences from Fresno Pacific College, completed his medical, doctoral, and pediatric residency training at Loma Linda University then completed a fellowship in pediatric hematology/oncology at Texas Children’s Hospital, Baylor College of Medicine. Dr. Lee is chair of the Cellular Therapy Strategy Group for the Pediatric Blood and Marrow Transplant Consortium, member of the NIH Recombinant DNA Advisory Committee, and member of the Cell Therapy Steering Committee for the Children’s Oncology Group.
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Hematology/Oncology & BMT
Physician Team
Blood and Marrow Transplant Clinical Team
Physician Team
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Bone Marrow Transplant Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Research
Lab(s)
Center for Childhood Cancer
Publications
de Souza Fernandez Pereira M, Carr DR, Gatti-Mays ME, Olsen MR, Setty BA, Shahwan KT, Lee DA. Natural Killer Cell Recognition and Control of Epithelial Cancers. Cancer J. 2022 Jul-Aug 01; 28: 263-269.
Fair SR, Schwind W, Julian D, Biel A, Guo G, Rutherford R, Ramadesikan S, Westfall J, Miller KE, Kararoudi MN, Hickey SE, Mosher TM, McBride KL, Neinast R, Fitch J, Lee D, White P, Wilson RK, Bedrosian TA, Koboldt DC, Hester ME. Cerebral organoids containing an AUTS2 missense variant model microcephaly. Brain. 2022 Jul 8;
Naeimi Kararoudi M, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, de Souza Fernandes Pereira M, Sezgin Y, Devine RD, Lyberger JM, Behbehani GK, Chakravarti N, Moriarity BS, Meyer K, Lee DA. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Rep Methods. 2022 Jun 20; 2: 100236.
Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo XM, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat SA, Rogers KA, Lee D, Muthusamy N, Byrd JC. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Adv. 2022 Apr 29;
Scorza BM, Mahachi KG, Cox AD, Toepp AJ, Pessoa-Pereira D, Tyrrell P, Buch J, Foltz JA, Lee D, Petersen CA. Role of NK-Like CD8+ T Cells during Asymptomatic Borrelia burgdorferi Infection. Infect Immun. 2022 Apr 13; e0055521.
Chu Y, Lamb M, Cairo MS, Lee DA. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Curr Treat Options Oncol. 2022 Mar; 23: 381-403.
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 Jan; 36: 155-164.
Naeimi Kararoudi M, Alsudayri A, Hill CL, Elmas E, Sezgin Y, Thakkar A, Hester ME, Malleske DT, Lee DA, Neal ML, Perry MR, Harvilchuck JA, Reynolds SD. Assessment of Beta-2 Microglobulin Gene Edited Airway Epithelial Stem Cells as a treatment for Sulfur Mustard Inhalation. Front Genome Ed. 2022; 4: 781531.
de Souza Fernandes Pereira M, Thakkar A, Lee DA. Non-invasive fluorescence imaging for tracking immune cells in preclinical models of immunotherapy. Methods Cell Biol. 2022; 167: 163-170.
Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, Lee DA, Naeimi Kararoudi M. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. Front Oncol. 2022; 12: 834002.
Silla L, Valim V, Pezzi A, da Silva M, Wilke I, Nobrega J, Vargas A, Amorin B, Correa B, Zambonato B, Scherer F, Merzoni J, Sekine L, Huls H, Cooper LJ, Paz A, Lee DA. Adoptive immunotherapy with double-bright (CD56bright /CD16bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study. Br J Haematol. 2021 Dec; 195: 710-721.
Trikha P, Moseman JE, Thakkar A, Campbell AR, Elmas E, Foltz JA, Chakravarti N, Fitch JR, Mardis ER, Lee DA. Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function. Blood Adv. 2021 Nov 23; 5: 4605-4618.
Rangarajan HG, Pereira MSF, Brazauskas R, St Martin A, Kussman A, Elmas E, Verneris MR, Gadalla SM, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Lee DA. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. Transplant Cell Ther. 2021 Nov; 27: 926.e1-926.e10.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021 Aug 14; 11: 146.
Chu Y, Nayyar G, Jiang S, Rosenblum JM, Soon-Shiong P, Safrit JT, Lee DA, Cairo MS. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. J Immunother Cancer. 2021 Jul; 9:
Wright M, Rangarajan H, Abu-Arja R, Auletta JJ, Lee D, Polishchuk V, Pai V, Taylor K, Bajwa RPS. Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2021 May 20; e14041.
Lamb MG, Rangarajan HG, Tullius BP, Lee DA. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res Ther. 2021 Mar 25; 12: 211.
Kisseberth WC, Lee DA. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma. Front Vet Sci. 2021; 8: 672361.
Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.
Chu Y, Awasthi A, Lee S, Edani D, Yin C, Hochberg J, Shah T, Chung TH, Ayello J, van de Ven C, Klein C, Lee D, Cairo MS. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget. 2020 Aug 11; 11: 3035-3047.
Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 2020 Aug 17; 22: 1214-1225.
Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. Cytotherapy. 2020 Jul; 22: 369-376.
Moseman JE, Foltz JA, Sorathia K, Heipertz EL, Lee DA. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells. Cytotherapy. 2020 Jun; 22: 322-328.
Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, Haymaker C, Bernatchez C, Lee DA, Watowich SS, Yee C. Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunol Res. 2020 Jun; 8: 794-805.
Verneris MR, Miller JS, Hsu KC, Wang T, Sees JA, Paczesny S, Rangarajan H, Lee DA, Spellman SR, Lee SJ. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020 Apr 14; 4: 1350-1356.
Judge SJ, Yanagisawa M, Sturgill IR, Bateni SB, Gingrich AA, Foltz JA, Lee DA, Modiano JF, Monjazeb AM, Culp WTN, Rebhun RB, Murphy WJ, Kent MS, Canter RJ. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS One. 2020; 15: e0224775.
Trikha P, Lee DA. The role of AhR in transcriptional regulation of immune cell development and function. Biochim Biophys Acta Rev Cancer. 2020 Jan; 1873: 188335.
Tullius BP, Setty BA, Lee DA. Natural Killer Cell Immunotherapy for Osteosarcoma. Adv Exp Med Biol. 2020; 1257: 141-154.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Vahidy FS, Haque ME, Rahbar MH, Zhu H, Rowan P, Aisiku IP, Lee DA, Juneja HS, Alderman S, Barreto AD, Suarez JI, Bambhroliya A, Hasan KM, Kassam MR, Aronowski J, Gee A, Cox CS Jr, Grotta JC, Savitz SI. Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. Stem Cells. 2019 Nov; 37: 1481-1491.
Ojo EO, Sharma AA, Liu R, Moreton S, Checkley-Luttge MA, Gupta K, Lee G, Lee DA, Otegbeye F, Sekaly RP, de Lima M, Wald DN. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep. 2019 Oct 17; 9: 14916.
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Lee DA. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. Immunol Rev. 2019 Jul; 290: 85-99.
Ray AK, Somanchi SS, Dastgheyb N, Lopez AA, Cobanoglu ZE, Geier B, Lee DA. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatr Blood Cancer. 2019 Jul 15; e27783.
Lamb MG, Lee DA. Donor-Derived Cytokine-Induced Killer Cells after Nonmyeloablative Transplant for Myeloid Neoplasms. Biol Blood Marrow Transplant. 2019 May 23;
Lamb MG, Lee DA. Donor Lymphocyte Infusions versus Cytokine-Induced Killer Cells for Hematologic Malignancies after Transplantation. Biol Blood Marrow Transplant. 2019 May 22;
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 409.
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 395-407.
Streltsova MA, Erokhina SA, Kanevskiy LM, Grechikhina MV, Kobyzeva PA, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-? Production, and Lifespan. Int J Mol Sci. 2019 Jan 21; 20:
Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, Roméro H, Selleri S, Béland K, Guiot M, Tremblay-Laganière C, Dicaire R, Barreiro L, Lee DA, Verhoeyen E, Haddad E. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector. Front Immunol. 2019; 10: 2873.
Schafer JR, Salzillo TC, Chakravarti N, Kararoudi MN, Trikha P, Foltz JA, Wang R, Li S, Lee DA. Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. J Allergy Clin Immunol. 2019 Jan; 143: 346-358.e6.
Foltz JA, Moseman JE, Thakkar A, Chakravarti N, Lee DA. TGFß Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion. Cancers (Basel). 2018 Nov 5; 10:
Wedekind MF, Haworth KB, Arnold M, Stanek JR, Lee D, Cripe TP. Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatr Blood Cancer. 2018 Nov; 65: e27313.
Adelman ZN, Albritton LM, Boris-Lawrie K, Buchmeier MJ, Cannon P, Cho M, DiGiusto D, Donahue JK, Federoff HJ, Hammarskjold ML, Hardison AD, Hearing P, Lee B, Lee DA, Porteus MH, Ross LF, Ross SR, Wooley DP, Zoloth L. Protect NIH's DNA advisory committee. Science. 2018 Oct 26; 362: 409-410.
Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, Caligiuri MA, Mishra A. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Adv. 2018 Aug 14; 2: 1818-1827.
Poznanski SM, Nham T, Chew MV, Lee AJ, Hammill JA, Fan IY, Butcher M, Bramson JL, Lee DA, Hirte HW, Ashkar AA. Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. Cancer Immunol Res. 2018 Jul 17;
Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;
Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant. 2018 May; 24: 895-908.
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018 Apr 19; 9: 1567.
Nham T, Poznanski SM, Fan IY, Shenouda MM, Chew MV, Lee AJ, Vahedi F, Karimi Y, Butcher M, Lee DA, Hirte H, Ashkar AA. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunol Immunother. 2018 Apr; 67: 575-587.
Nham T, Poznanski SM, Fan IY, Vahedi F, Shenouda MM, Lee AJ, Chew MV, Hogg RT, Lee DA, Ashkar AA. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. J Immunother. 2018 Feb/Mar; 41: 64-72.
Rangarajan HG, Stanek JR, Abu-Arja R, Bajwa RPS, Auletta JJ, Lee DA, O'Brien SH, Kumar R. Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. Biol Blood Marrow Transplant. 2018 Feb; 24: 337-342.
Naeimi Kararoudi M, Hejazi SS, Elmas E, Hellström M, Naeimi Kararoudi M, Padma AM, Lee D, Dolatshad H. Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Gene Editing Technique in Xenotransplantation. Front Immunol. 2018; 9: 1711.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Correction: Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0197008.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0191358.
Streltsova MA, Erokhina SA, Kanevskiy LM, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Analysis of NK cell clones obtained using interleukin-2 and gene-modified K562 cells revealed the ability of "senescent" NK cells to lose CD57 expression and start expressing NKG2A. PLoS One. 2018; 13: e0208469.
View More Publications
Education
Date of Appointment at Nationwide Children’s Hospital: 07/01/2016
Board Certifications
Pediatric Hematology Oncology
Fellowship
Texas Children’s Hospital
Date Completed: 06/30/2003
Residency
Loma Linda Children’s Hospital
Date Completed: 06/30/1999
Medical School
Loma Linda University School of Medicine
Date Completed: 06/01/1996
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Dean A. Lee
Biography
Dean Anthony Lee, MD, PhD, is a physician in the Division of Hematology and Oncology at Nationwide Children’s Hospital and director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children’s Hospital and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He is a professor of pediatrics at The Ohio State University College of Medicine and the DiMarco Family Endowed Chair in Cell Based Therapy. Dr. Lee earned his bachelor’s degree in natural sciences from Fresno Pacific College, completed his medical, doctoral, and pediatric residency training at Loma Linda University then completed a fellowship in pediatric hematology/oncology at Texas Children’s Hospital, Baylor College of Medicine. Dr. Lee is chair of the Cellular Therapy Strategy Group for the Pediatric Blood and Marrow Transplant Consortium, member of the NIH Recombinant DNA Advisory Committee, and member of the Cell Therapy Steering Committee for the Children’s Oncology Group.
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Hematology/Oncology & BMT
Physician Team
Blood and Marrow Transplant Clinical Team
Physician Team
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Bone Marrow Transplant Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Research
Lab(s)
Center for Childhood Cancer
Publications
de Souza Fernandez Pereira M, Carr DR, Gatti-Mays ME, Olsen MR, Setty BA, Shahwan KT, Lee DA. Natural Killer Cell Recognition and Control of Epithelial Cancers. Cancer J. 2022 Jul-Aug 01; 28: 263-269.
Fair SR, Schwind W, Julian D, Biel A, Guo G, Rutherford R, Ramadesikan S, Westfall J, Miller KE, Kararoudi MN, Hickey SE, Mosher TM, McBride KL, Neinast R, Fitch J, Lee D, White P, Wilson RK, Bedrosian TA, Koboldt DC, Hester ME. Cerebral organoids containing an AUTS2 missense variant model microcephaly. Brain. 2022 Jul 8;
Naeimi Kararoudi M, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, de Souza Fernandes Pereira M, Sezgin Y, Devine RD, Lyberger JM, Behbehani GK, Chakravarti N, Moriarity BS, Meyer K, Lee DA. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Rep Methods. 2022 Jun 20; 2: 100236.
Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo XM, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat SA, Rogers KA, Lee D, Muthusamy N, Byrd JC. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Adv. 2022 Apr 29;
Scorza BM, Mahachi KG, Cox AD, Toepp AJ, Pessoa-Pereira D, Tyrrell P, Buch J, Foltz JA, Lee D, Petersen CA. Role of NK-Like CD8+ T Cells during Asymptomatic Borrelia burgdorferi Infection. Infect Immun. 2022 Apr 13; e0055521.
Chu Y, Lamb M, Cairo MS, Lee DA. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Curr Treat Options Oncol. 2022 Mar; 23: 381-403.
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 Jan; 36: 155-164.
Naeimi Kararoudi M, Alsudayri A, Hill CL, Elmas E, Sezgin Y, Thakkar A, Hester ME, Malleske DT, Lee DA, Neal ML, Perry MR, Harvilchuck JA, Reynolds SD. Assessment of Beta-2 Microglobulin Gene Edited Airway Epithelial Stem Cells as a treatment for Sulfur Mustard Inhalation. Front Genome Ed. 2022; 4: 781531.
de Souza Fernandes Pereira M, Thakkar A, Lee DA. Non-invasive fluorescence imaging for tracking immune cells in preclinical models of immunotherapy. Methods Cell Biol. 2022; 167: 163-170.
Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, Lee DA, Naeimi Kararoudi M. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. Front Oncol. 2022; 12: 834002.
Silla L, Valim V, Pezzi A, da Silva M, Wilke I, Nobrega J, Vargas A, Amorin B, Correa B, Zambonato B, Scherer F, Merzoni J, Sekine L, Huls H, Cooper LJ, Paz A, Lee DA. Adoptive immunotherapy with double-bright (CD56bright /CD16bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study. Br J Haematol. 2021 Dec; 195: 710-721.
Trikha P, Moseman JE, Thakkar A, Campbell AR, Elmas E, Foltz JA, Chakravarti N, Fitch JR, Mardis ER, Lee DA. Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function. Blood Adv. 2021 Nov 23; 5: 4605-4618.
Rangarajan HG, Pereira MSF, Brazauskas R, St Martin A, Kussman A, Elmas E, Verneris MR, Gadalla SM, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Lee DA. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. Transplant Cell Ther. 2021 Nov; 27: 926.e1-926.e10.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021 Aug 14; 11: 146.
Chu Y, Nayyar G, Jiang S, Rosenblum JM, Soon-Shiong P, Safrit JT, Lee DA, Cairo MS. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. J Immunother Cancer. 2021 Jul; 9:
Wright M, Rangarajan H, Abu-Arja R, Auletta JJ, Lee D, Polishchuk V, Pai V, Taylor K, Bajwa RPS. Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2021 May 20; e14041.
Lamb MG, Rangarajan HG, Tullius BP, Lee DA. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res Ther. 2021 Mar 25; 12: 211.
Kisseberth WC, Lee DA. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma. Front Vet Sci. 2021; 8: 672361.
Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.
Chu Y, Awasthi A, Lee S, Edani D, Yin C, Hochberg J, Shah T, Chung TH, Ayello J, van de Ven C, Klein C, Lee D, Cairo MS. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget. 2020 Aug 11; 11: 3035-3047.
Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 2020 Aug 17; 22: 1214-1225.
Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. Cytotherapy. 2020 Jul; 22: 369-376.
Moseman JE, Foltz JA, Sorathia K, Heipertz EL, Lee DA. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells. Cytotherapy. 2020 Jun; 22: 322-328.
Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, Haymaker C, Bernatchez C, Lee DA, Watowich SS, Yee C. Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunol Res. 2020 Jun; 8: 794-805.
Verneris MR, Miller JS, Hsu KC, Wang T, Sees JA, Paczesny S, Rangarajan H, Lee DA, Spellman SR, Lee SJ. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020 Apr 14; 4: 1350-1356.
Judge SJ, Yanagisawa M, Sturgill IR, Bateni SB, Gingrich AA, Foltz JA, Lee DA, Modiano JF, Monjazeb AM, Culp WTN, Rebhun RB, Murphy WJ, Kent MS, Canter RJ. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS One. 2020; 15: e0224775.
Trikha P, Lee DA. The role of AhR in transcriptional regulation of immune cell development and function. Biochim Biophys Acta Rev Cancer. 2020 Jan; 1873: 188335.
Tullius BP, Setty BA, Lee DA. Natural Killer Cell Immunotherapy for Osteosarcoma. Adv Exp Med Biol. 2020; 1257: 141-154.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Vahidy FS, Haque ME, Rahbar MH, Zhu H, Rowan P, Aisiku IP, Lee DA, Juneja HS, Alderman S, Barreto AD, Suarez JI, Bambhroliya A, Hasan KM, Kassam MR, Aronowski J, Gee A, Cox CS Jr, Grotta JC, Savitz SI. Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. Stem Cells. 2019 Nov; 37: 1481-1491.
Ojo EO, Sharma AA, Liu R, Moreton S, Checkley-Luttge MA, Gupta K, Lee G, Lee DA, Otegbeye F, Sekaly RP, de Lima M, Wald DN. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep. 2019 Oct 17; 9: 14916.
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Lee DA. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. Immunol Rev. 2019 Jul; 290: 85-99.
Ray AK, Somanchi SS, Dastgheyb N, Lopez AA, Cobanoglu ZE, Geier B, Lee DA. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatr Blood Cancer. 2019 Jul 15; e27783.
Lamb MG, Lee DA. Donor-Derived Cytokine-Induced Killer Cells after Nonmyeloablative Transplant for Myeloid Neoplasms. Biol Blood Marrow Transplant. 2019 May 23;
Lamb MG, Lee DA. Donor Lymphocyte Infusions versus Cytokine-Induced Killer Cells for Hematologic Malignancies after Transplantation. Biol Blood Marrow Transplant. 2019 May 22;
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 409.
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 395-407.
Streltsova MA, Erokhina SA, Kanevskiy LM, Grechikhina MV, Kobyzeva PA, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-? Production, and Lifespan. Int J Mol Sci. 2019 Jan 21; 20:
Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, Roméro H, Selleri S, Béland K, Guiot M, Tremblay-Laganière C, Dicaire R, Barreiro L, Lee DA, Verhoeyen E, Haddad E. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector. Front Immunol. 2019; 10: 2873.
Schafer JR, Salzillo TC, Chakravarti N, Kararoudi MN, Trikha P, Foltz JA, Wang R, Li S, Lee DA. Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. J Allergy Clin Immunol. 2019 Jan; 143: 346-358.e6.
Foltz JA, Moseman JE, Thakkar A, Chakravarti N, Lee DA. TGFß Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion. Cancers (Basel). 2018 Nov 5; 10:
Wedekind MF, Haworth KB, Arnold M, Stanek JR, Lee D, Cripe TP. Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatr Blood Cancer. 2018 Nov; 65: e27313.
Adelman ZN, Albritton LM, Boris-Lawrie K, Buchmeier MJ, Cannon P, Cho M, DiGiusto D, Donahue JK, Federoff HJ, Hammarskjold ML, Hardison AD, Hearing P, Lee B, Lee DA, Porteus MH, Ross LF, Ross SR, Wooley DP, Zoloth L. Protect NIH's DNA advisory committee. Science. 2018 Oct 26; 362: 409-410.
Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, Caligiuri MA, Mishra A. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Adv. 2018 Aug 14; 2: 1818-1827.
Poznanski SM, Nham T, Chew MV, Lee AJ, Hammill JA, Fan IY, Butcher M, Bramson JL, Lee DA, Hirte HW, Ashkar AA. Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. Cancer Immunol Res. 2018 Jul 17;
Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;
Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant. 2018 May; 24: 895-908.
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018 Apr 19; 9: 1567.
Nham T, Poznanski SM, Fan IY, Shenouda MM, Chew MV, Lee AJ, Vahedi F, Karimi Y, Butcher M, Lee DA, Hirte H, Ashkar AA. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunol Immunother. 2018 Apr; 67: 575-587.
Nham T, Poznanski SM, Fan IY, Vahedi F, Shenouda MM, Lee AJ, Chew MV, Hogg RT, Lee DA, Ashkar AA. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. J Immunother. 2018 Feb/Mar; 41: 64-72.
Rangarajan HG, Stanek JR, Abu-Arja R, Bajwa RPS, Auletta JJ, Lee DA, O'Brien SH, Kumar R. Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. Biol Blood Marrow Transplant. 2018 Feb; 24: 337-342.
Naeimi Kararoudi M, Hejazi SS, Elmas E, Hellström M, Naeimi Kararoudi M, Padma AM, Lee D, Dolatshad H. Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Gene Editing Technique in Xenotransplantation. Front Immunol. 2018; 9: 1711.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Correction: Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0197008.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0191358.
Streltsova MA, Erokhina SA, Kanevskiy LM, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Analysis of NK cell clones obtained using interleukin-2 and gene-modified K562 cells revealed the ability of "senescent" NK cells to lose CD57 expression and start expressing NKG2A. PLoS One. 2018; 13: e0208469.
View More Publications
Education
Date of Appointment at Nationwide Children’s Hospital: 07/01/2016
Board Certifications
Pediatric Hematology Oncology
Fellowship
Texas Children’s Hospital
Date Completed: 06/30/2003
Residency
Loma Linda Children’s Hospital
Date Completed: 06/30/1999
Medical School
Loma Linda University School of Medicine
Date Completed: 06/01/1996
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Dean A. Lee
Contact Information
- Call us at:
- (614) 722-3550
- Fax us at:
- (614) 722-3369
- PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Dean A. Lee
Biography
Dean Anthony Lee, MD, PhD, is a physician in the Division of Hematology and Oncology at Nationwide Children’s Hospital and director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children’s Hospital and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He is a professor of pediatrics at The Ohio State University College of Medicine and the DiMarco Family Endowed Chair in Cell Based Therapy. Dr. Lee earned his bachelor’s degree in natural sciences from Fresno Pacific College, completed his medical, doctoral, and pediatric residency training at Loma Linda University then completed a fellowship in pediatric hematology/oncology at Texas Children’s Hospital, Baylor College of Medicine. Dr. Lee is chair of the Cellular Therapy Strategy Group for the Pediatric Blood and Marrow Transplant Consortium, member of the NIH Recombinant DNA Advisory Committee, and member of the Cell Therapy Steering Committee for the Children’s Oncology Group.
Biography
Dean Anthony Lee, MD, PhD, is a physician in the Division of Hematology and Oncology at Nationwide Children’s Hospital and director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children’s Hospital and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He is a professor of pediatrics at The Ohio State University College of Medicine and the DiMarco Family Endowed Chair in Cell Based Therapy. Dr. Lee earned his bachelor’s degree in natural sciences from Fresno Pacific College, completed his medical, doctoral, and pediatric residency training at Loma Linda University then completed a fellowship in pediatric hematology/oncology at Texas Children’s Hospital, Baylor College of Medicine. Dr. Lee is chair of the Cellular Therapy Strategy Group for the Pediatric Blood and Marrow Transplant Consortium, member of the NIH Recombinant DNA Advisory Committee, and member of the Cell Therapy Steering Committee for the Children’s Oncology Group.
Biography
Dean Anthony Lee, MD, PhD, is a physician in the Division of Hematology and Oncology at Nationwide Children’s Hospital and director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children’s Hospital and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He is a professor of pediatrics at The Ohio State University College of Medicine and the DiMarco Family Endowed Chair in Cell Based Therapy. Dr. Lee earned his bachelor’s degree in natural sciences from Fresno Pacific College, completed his medical, doctoral, and pediatric residency training at Loma Linda University then completed a fellowship in pediatric hematology/oncology at Texas Children’s Hospital, Baylor College of Medicine. Dr. Lee is chair of the Cellular Therapy Strategy Group for the Pediatric Blood and Marrow Transplant Consortium, member of the NIH Recombinant DNA Advisory Committee, and member of the Cell Therapy Steering Committee for the Children’s Oncology Group.
Dean Anthony Lee, MD, PhD, is a physician in the Division of Hematology and Oncology at Nationwide Children’s Hospital and director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children’s Hospital and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He is a professor of pediatrics at The Ohio State University College of Medicine and the DiMarco Family Endowed Chair in Cell Based Therapy. Dr. Lee earned his bachelor’s degree in natural sciences from Fresno Pacific College, completed his medical, doctoral, and pediatric residency training at Loma Linda University then completed a fellowship in pediatric hematology/oncology at Texas Children’s Hospital, Baylor College of Medicine. Dr. Lee is chair of the Cellular Therapy Strategy Group for the Pediatric Blood and Marrow Transplant Consortium, member of the NIH Recombinant DNA Advisory Committee, and member of the Cell Therapy Steering Committee for the Children’s Oncology Group.
Dean Anthony Lee, MD, PhD, is a physician in the Division of Hematology and Oncology at Nationwide Children’s Hospital and director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children’s Hospital and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He is a professor of pediatrics at The Ohio State University College of Medicine and the DiMarco Family Endowed Chair in Cell Based Therapy.
Dr. Lee earned his bachelor’s degree in natural sciences from Fresno Pacific College, completed his medical, doctoral, and pediatric residency training at Loma Linda University then completed a fellowship in pediatric hematology/oncology at Texas Children’s Hospital, Baylor College of Medicine. Dr. Lee is chair of the Cellular Therapy Strategy Group for the Pediatric Blood and Marrow Transplant Consortium, member of the NIH Recombinant DNA Advisory Committee, and member of the Cell Therapy Steering Committee for the Children’s Oncology Group.
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Locations
Main Campus of Nationwide Children’s Hospital
Locations
Main Campus of Nationwide Children’s Hospital
Locations
Main Campus of Nationwide Children’s Hospital
- Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Hematology/Oncology & BMT
Physician Team
Blood and Marrow Transplant Clinical Team
Physician Team
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Bone Marrow Transplant Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Academic and Clinical Areas
Hematology/Oncology & BMT
Physician Team
Blood and Marrow Transplant Clinical Team
Physician Team
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Bone Marrow Transplant Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Academic and Clinical Areas
Hematology/Oncology & BMT
Physician Team
Blood and Marrow Transplant Clinical Team
Physician Team
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Bone Marrow Transplant Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Hematology/Oncology & BMT
Physician Team
Blood and Marrow Transplant Clinical Team
Physician Team
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Bone Marrow Transplant Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
- Hematology/Oncology & BMT
- Physician Team
- Blood and Marrow Transplant Clinical Team
- Physician Team
- Center for Childhood Cancer
- Principal Investigator
- Hematology, Oncology and BMT Fellowship
- Faculty
- Bone Marrow Transplant Fellowship
- Faculty
- Primary Department
- Pediatrics
- Primary Section
- Hematology & Oncology
Research
Lab(s)
Center for Childhood Cancer
Publications
de Souza Fernandez Pereira M, Carr DR, Gatti-Mays ME, Olsen MR, Setty BA, Shahwan KT, Lee DA. Natural Killer Cell Recognition and Control of Epithelial Cancers. Cancer J. 2022 Jul-Aug 01; 28: 263-269.
Fair SR, Schwind W, Julian D, Biel A, Guo G, Rutherford R, Ramadesikan S, Westfall J, Miller KE, Kararoudi MN, Hickey SE, Mosher TM, McBride KL, Neinast R, Fitch J, Lee D, White P, Wilson RK, Bedrosian TA, Koboldt DC, Hester ME. Cerebral organoids containing an AUTS2 missense variant model microcephaly. Brain. 2022 Jul 8;
Naeimi Kararoudi M, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, de Souza Fernandes Pereira M, Sezgin Y, Devine RD, Lyberger JM, Behbehani GK, Chakravarti N, Moriarity BS, Meyer K, Lee DA. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Rep Methods. 2022 Jun 20; 2: 100236.
Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo XM, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat SA, Rogers KA, Lee D, Muthusamy N, Byrd JC. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Adv. 2022 Apr 29;
Scorza BM, Mahachi KG, Cox AD, Toepp AJ, Pessoa-Pereira D, Tyrrell P, Buch J, Foltz JA, Lee D, Petersen CA. Role of NK-Like CD8+ T Cells during Asymptomatic Borrelia burgdorferi Infection. Infect Immun. 2022 Apr 13; e0055521.
Chu Y, Lamb M, Cairo MS, Lee DA. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Curr Treat Options Oncol. 2022 Mar; 23: 381-403.
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 Jan; 36: 155-164.
Naeimi Kararoudi M, Alsudayri A, Hill CL, Elmas E, Sezgin Y, Thakkar A, Hester ME, Malleske DT, Lee DA, Neal ML, Perry MR, Harvilchuck JA, Reynolds SD. Assessment of Beta-2 Microglobulin Gene Edited Airway Epithelial Stem Cells as a treatment for Sulfur Mustard Inhalation. Front Genome Ed. 2022; 4: 781531.
de Souza Fernandes Pereira M, Thakkar A, Lee DA. Non-invasive fluorescence imaging for tracking immune cells in preclinical models of immunotherapy. Methods Cell Biol. 2022; 167: 163-170.
Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, Lee DA, Naeimi Kararoudi M. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. Front Oncol. 2022; 12: 834002.
Silla L, Valim V, Pezzi A, da Silva M, Wilke I, Nobrega J, Vargas A, Amorin B, Correa B, Zambonato B, Scherer F, Merzoni J, Sekine L, Huls H, Cooper LJ, Paz A, Lee DA. Adoptive immunotherapy with double-bright (CD56bright /CD16bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study. Br J Haematol. 2021 Dec; 195: 710-721.
Trikha P, Moseman JE, Thakkar A, Campbell AR, Elmas E, Foltz JA, Chakravarti N, Fitch JR, Mardis ER, Lee DA. Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function. Blood Adv. 2021 Nov 23; 5: 4605-4618.
Rangarajan HG, Pereira MSF, Brazauskas R, St Martin A, Kussman A, Elmas E, Verneris MR, Gadalla SM, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Lee DA. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. Transplant Cell Ther. 2021 Nov; 27: 926.e1-926.e10.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021 Aug 14; 11: 146.
Chu Y, Nayyar G, Jiang S, Rosenblum JM, Soon-Shiong P, Safrit JT, Lee DA, Cairo MS. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. J Immunother Cancer. 2021 Jul; 9:
Wright M, Rangarajan H, Abu-Arja R, Auletta JJ, Lee D, Polishchuk V, Pai V, Taylor K, Bajwa RPS. Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2021 May 20; e14041.
Lamb MG, Rangarajan HG, Tullius BP, Lee DA. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res Ther. 2021 Mar 25; 12: 211.
Kisseberth WC, Lee DA. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma. Front Vet Sci. 2021; 8: 672361.
Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.
Chu Y, Awasthi A, Lee S, Edani D, Yin C, Hochberg J, Shah T, Chung TH, Ayello J, van de Ven C, Klein C, Lee D, Cairo MS. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget. 2020 Aug 11; 11: 3035-3047.
Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 2020 Aug 17; 22: 1214-1225.
Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. Cytotherapy. 2020 Jul; 22: 369-376.
Moseman JE, Foltz JA, Sorathia K, Heipertz EL, Lee DA. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells. Cytotherapy. 2020 Jun; 22: 322-328.
Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, Haymaker C, Bernatchez C, Lee DA, Watowich SS, Yee C. Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunol Res. 2020 Jun; 8: 794-805.
Verneris MR, Miller JS, Hsu KC, Wang T, Sees JA, Paczesny S, Rangarajan H, Lee DA, Spellman SR, Lee SJ. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020 Apr 14; 4: 1350-1356.
Judge SJ, Yanagisawa M, Sturgill IR, Bateni SB, Gingrich AA, Foltz JA, Lee DA, Modiano JF, Monjazeb AM, Culp WTN, Rebhun RB, Murphy WJ, Kent MS, Canter RJ. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS One. 2020; 15: e0224775.
Trikha P, Lee DA. The role of AhR in transcriptional regulation of immune cell development and function. Biochim Biophys Acta Rev Cancer. 2020 Jan; 1873: 188335.
Tullius BP, Setty BA, Lee DA. Natural Killer Cell Immunotherapy for Osteosarcoma. Adv Exp Med Biol. 2020; 1257: 141-154.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Vahidy FS, Haque ME, Rahbar MH, Zhu H, Rowan P, Aisiku IP, Lee DA, Juneja HS, Alderman S, Barreto AD, Suarez JI, Bambhroliya A, Hasan KM, Kassam MR, Aronowski J, Gee A, Cox CS Jr, Grotta JC, Savitz SI. Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. Stem Cells. 2019 Nov; 37: 1481-1491.
Ojo EO, Sharma AA, Liu R, Moreton S, Checkley-Luttge MA, Gupta K, Lee G, Lee DA, Otegbeye F, Sekaly RP, de Lima M, Wald DN. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep. 2019 Oct 17; 9: 14916.
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Lee DA. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. Immunol Rev. 2019 Jul; 290: 85-99.
Ray AK, Somanchi SS, Dastgheyb N, Lopez AA, Cobanoglu ZE, Geier B, Lee DA. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatr Blood Cancer. 2019 Jul 15; e27783.
Lamb MG, Lee DA. Donor-Derived Cytokine-Induced Killer Cells after Nonmyeloablative Transplant for Myeloid Neoplasms. Biol Blood Marrow Transplant. 2019 May 23;
Lamb MG, Lee DA. Donor Lymphocyte Infusions versus Cytokine-Induced Killer Cells for Hematologic Malignancies after Transplantation. Biol Blood Marrow Transplant. 2019 May 22;
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 409.
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 395-407.
Streltsova MA, Erokhina SA, Kanevskiy LM, Grechikhina MV, Kobyzeva PA, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-? Production, and Lifespan. Int J Mol Sci. 2019 Jan 21; 20:
Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, Roméro H, Selleri S, Béland K, Guiot M, Tremblay-Laganière C, Dicaire R, Barreiro L, Lee DA, Verhoeyen E, Haddad E. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector. Front Immunol. 2019; 10: 2873.
Schafer JR, Salzillo TC, Chakravarti N, Kararoudi MN, Trikha P, Foltz JA, Wang R, Li S, Lee DA. Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. J Allergy Clin Immunol. 2019 Jan; 143: 346-358.e6.
Foltz JA, Moseman JE, Thakkar A, Chakravarti N, Lee DA. TGFß Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion. Cancers (Basel). 2018 Nov 5; 10:
Wedekind MF, Haworth KB, Arnold M, Stanek JR, Lee D, Cripe TP. Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatr Blood Cancer. 2018 Nov; 65: e27313.
Adelman ZN, Albritton LM, Boris-Lawrie K, Buchmeier MJ, Cannon P, Cho M, DiGiusto D, Donahue JK, Federoff HJ, Hammarskjold ML, Hardison AD, Hearing P, Lee B, Lee DA, Porteus MH, Ross LF, Ross SR, Wooley DP, Zoloth L. Protect NIH's DNA advisory committee. Science. 2018 Oct 26; 362: 409-410.
Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, Caligiuri MA, Mishra A. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Adv. 2018 Aug 14; 2: 1818-1827.
Poznanski SM, Nham T, Chew MV, Lee AJ, Hammill JA, Fan IY, Butcher M, Bramson JL, Lee DA, Hirte HW, Ashkar AA. Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. Cancer Immunol Res. 2018 Jul 17;
Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;
Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant. 2018 May; 24: 895-908.
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018 Apr 19; 9: 1567.
Nham T, Poznanski SM, Fan IY, Shenouda MM, Chew MV, Lee AJ, Vahedi F, Karimi Y, Butcher M, Lee DA, Hirte H, Ashkar AA. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunol Immunother. 2018 Apr; 67: 575-587.
Nham T, Poznanski SM, Fan IY, Vahedi F, Shenouda MM, Lee AJ, Chew MV, Hogg RT, Lee DA, Ashkar AA. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. J Immunother. 2018 Feb/Mar; 41: 64-72.
Rangarajan HG, Stanek JR, Abu-Arja R, Bajwa RPS, Auletta JJ, Lee DA, O'Brien SH, Kumar R. Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. Biol Blood Marrow Transplant. 2018 Feb; 24: 337-342.
Naeimi Kararoudi M, Hejazi SS, Elmas E, Hellström M, Naeimi Kararoudi M, Padma AM, Lee D, Dolatshad H. Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Gene Editing Technique in Xenotransplantation. Front Immunol. 2018; 9: 1711.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Correction: Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0197008.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0191358.
Streltsova MA, Erokhina SA, Kanevskiy LM, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Analysis of NK cell clones obtained using interleukin-2 and gene-modified K562 cells revealed the ability of "senescent" NK cells to lose CD57 expression and start expressing NKG2A. PLoS One. 2018; 13: e0208469.
View More Publications
Research
Lab(s)
Center for Childhood Cancer
Publications
de Souza Fernandez Pereira M, Carr DR, Gatti-Mays ME, Olsen MR, Setty BA, Shahwan KT, Lee DA. Natural Killer Cell Recognition and Control of Epithelial Cancers. Cancer J. 2022 Jul-Aug 01; 28: 263-269.
Fair SR, Schwind W, Julian D, Biel A, Guo G, Rutherford R, Ramadesikan S, Westfall J, Miller KE, Kararoudi MN, Hickey SE, Mosher TM, McBride KL, Neinast R, Fitch J, Lee D, White P, Wilson RK, Bedrosian TA, Koboldt DC, Hester ME. Cerebral organoids containing an AUTS2 missense variant model microcephaly. Brain. 2022 Jul 8;
Naeimi Kararoudi M, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, de Souza Fernandes Pereira M, Sezgin Y, Devine RD, Lyberger JM, Behbehani GK, Chakravarti N, Moriarity BS, Meyer K, Lee DA. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Rep Methods. 2022 Jun 20; 2: 100236.
Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo XM, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat SA, Rogers KA, Lee D, Muthusamy N, Byrd JC. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Adv. 2022 Apr 29;
Scorza BM, Mahachi KG, Cox AD, Toepp AJ, Pessoa-Pereira D, Tyrrell P, Buch J, Foltz JA, Lee D, Petersen CA. Role of NK-Like CD8+ T Cells during Asymptomatic Borrelia burgdorferi Infection. Infect Immun. 2022 Apr 13; e0055521.
Chu Y, Lamb M, Cairo MS, Lee DA. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Curr Treat Options Oncol. 2022 Mar; 23: 381-403.
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 Jan; 36: 155-164.
Naeimi Kararoudi M, Alsudayri A, Hill CL, Elmas E, Sezgin Y, Thakkar A, Hester ME, Malleske DT, Lee DA, Neal ML, Perry MR, Harvilchuck JA, Reynolds SD. Assessment of Beta-2 Microglobulin Gene Edited Airway Epithelial Stem Cells as a treatment for Sulfur Mustard Inhalation. Front Genome Ed. 2022; 4: 781531.
de Souza Fernandes Pereira M, Thakkar A, Lee DA. Non-invasive fluorescence imaging for tracking immune cells in preclinical models of immunotherapy. Methods Cell Biol. 2022; 167: 163-170.
Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, Lee DA, Naeimi Kararoudi M. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. Front Oncol. 2022; 12: 834002.
Silla L, Valim V, Pezzi A, da Silva M, Wilke I, Nobrega J, Vargas A, Amorin B, Correa B, Zambonato B, Scherer F, Merzoni J, Sekine L, Huls H, Cooper LJ, Paz A, Lee DA. Adoptive immunotherapy with double-bright (CD56bright /CD16bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study. Br J Haematol. 2021 Dec; 195: 710-721.
Trikha P, Moseman JE, Thakkar A, Campbell AR, Elmas E, Foltz JA, Chakravarti N, Fitch JR, Mardis ER, Lee DA. Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function. Blood Adv. 2021 Nov 23; 5: 4605-4618.
Rangarajan HG, Pereira MSF, Brazauskas R, St Martin A, Kussman A, Elmas E, Verneris MR, Gadalla SM, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Lee DA. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. Transplant Cell Ther. 2021 Nov; 27: 926.e1-926.e10.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021 Aug 14; 11: 146.
Chu Y, Nayyar G, Jiang S, Rosenblum JM, Soon-Shiong P, Safrit JT, Lee DA, Cairo MS. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. J Immunother Cancer. 2021 Jul; 9:
Wright M, Rangarajan H, Abu-Arja R, Auletta JJ, Lee D, Polishchuk V, Pai V, Taylor K, Bajwa RPS. Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2021 May 20; e14041.
Lamb MG, Rangarajan HG, Tullius BP, Lee DA. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res Ther. 2021 Mar 25; 12: 211.
Kisseberth WC, Lee DA. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma. Front Vet Sci. 2021; 8: 672361.
Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.
Chu Y, Awasthi A, Lee S, Edani D, Yin C, Hochberg J, Shah T, Chung TH, Ayello J, van de Ven C, Klein C, Lee D, Cairo MS. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget. 2020 Aug 11; 11: 3035-3047.
Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 2020 Aug 17; 22: 1214-1225.
Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. Cytotherapy. 2020 Jul; 22: 369-376.
Moseman JE, Foltz JA, Sorathia K, Heipertz EL, Lee DA. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells. Cytotherapy. 2020 Jun; 22: 322-328.
Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, Haymaker C, Bernatchez C, Lee DA, Watowich SS, Yee C. Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunol Res. 2020 Jun; 8: 794-805.
Verneris MR, Miller JS, Hsu KC, Wang T, Sees JA, Paczesny S, Rangarajan H, Lee DA, Spellman SR, Lee SJ. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020 Apr 14; 4: 1350-1356.
Judge SJ, Yanagisawa M, Sturgill IR, Bateni SB, Gingrich AA, Foltz JA, Lee DA, Modiano JF, Monjazeb AM, Culp WTN, Rebhun RB, Murphy WJ, Kent MS, Canter RJ. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS One. 2020; 15: e0224775.
Trikha P, Lee DA. The role of AhR in transcriptional regulation of immune cell development and function. Biochim Biophys Acta Rev Cancer. 2020 Jan; 1873: 188335.
Tullius BP, Setty BA, Lee DA. Natural Killer Cell Immunotherapy for Osteosarcoma. Adv Exp Med Biol. 2020; 1257: 141-154.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Vahidy FS, Haque ME, Rahbar MH, Zhu H, Rowan P, Aisiku IP, Lee DA, Juneja HS, Alderman S, Barreto AD, Suarez JI, Bambhroliya A, Hasan KM, Kassam MR, Aronowski J, Gee A, Cox CS Jr, Grotta JC, Savitz SI. Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. Stem Cells. 2019 Nov; 37: 1481-1491.
Ojo EO, Sharma AA, Liu R, Moreton S, Checkley-Luttge MA, Gupta K, Lee G, Lee DA, Otegbeye F, Sekaly RP, de Lima M, Wald DN. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep. 2019 Oct 17; 9: 14916.
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Lee DA. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. Immunol Rev. 2019 Jul; 290: 85-99.
Ray AK, Somanchi SS, Dastgheyb N, Lopez AA, Cobanoglu ZE, Geier B, Lee DA. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatr Blood Cancer. 2019 Jul 15; e27783.
Lamb MG, Lee DA. Donor-Derived Cytokine-Induced Killer Cells after Nonmyeloablative Transplant for Myeloid Neoplasms. Biol Blood Marrow Transplant. 2019 May 23;
Lamb MG, Lee DA. Donor Lymphocyte Infusions versus Cytokine-Induced Killer Cells for Hematologic Malignancies after Transplantation. Biol Blood Marrow Transplant. 2019 May 22;
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 409.
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 395-407.
Streltsova MA, Erokhina SA, Kanevskiy LM, Grechikhina MV, Kobyzeva PA, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-? Production, and Lifespan. Int J Mol Sci. 2019 Jan 21; 20:
Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, Roméro H, Selleri S, Béland K, Guiot M, Tremblay-Laganière C, Dicaire R, Barreiro L, Lee DA, Verhoeyen E, Haddad E. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector. Front Immunol. 2019; 10: 2873.
Schafer JR, Salzillo TC, Chakravarti N, Kararoudi MN, Trikha P, Foltz JA, Wang R, Li S, Lee DA. Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. J Allergy Clin Immunol. 2019 Jan; 143: 346-358.e6.
Foltz JA, Moseman JE, Thakkar A, Chakravarti N, Lee DA. TGFß Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion. Cancers (Basel). 2018 Nov 5; 10:
Wedekind MF, Haworth KB, Arnold M, Stanek JR, Lee D, Cripe TP. Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatr Blood Cancer. 2018 Nov; 65: e27313.
Adelman ZN, Albritton LM, Boris-Lawrie K, Buchmeier MJ, Cannon P, Cho M, DiGiusto D, Donahue JK, Federoff HJ, Hammarskjold ML, Hardison AD, Hearing P, Lee B, Lee DA, Porteus MH, Ross LF, Ross SR, Wooley DP, Zoloth L. Protect NIH's DNA advisory committee. Science. 2018 Oct 26; 362: 409-410.
Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, Caligiuri MA, Mishra A. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Adv. 2018 Aug 14; 2: 1818-1827.
Poznanski SM, Nham T, Chew MV, Lee AJ, Hammill JA, Fan IY, Butcher M, Bramson JL, Lee DA, Hirte HW, Ashkar AA. Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. Cancer Immunol Res. 2018 Jul 17;
Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;
Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant. 2018 May; 24: 895-908.
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018 Apr 19; 9: 1567.
Nham T, Poznanski SM, Fan IY, Shenouda MM, Chew MV, Lee AJ, Vahedi F, Karimi Y, Butcher M, Lee DA, Hirte H, Ashkar AA. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunol Immunother. 2018 Apr; 67: 575-587.
Nham T, Poznanski SM, Fan IY, Vahedi F, Shenouda MM, Lee AJ, Chew MV, Hogg RT, Lee DA, Ashkar AA. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. J Immunother. 2018 Feb/Mar; 41: 64-72.
Rangarajan HG, Stanek JR, Abu-Arja R, Bajwa RPS, Auletta JJ, Lee DA, O'Brien SH, Kumar R. Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. Biol Blood Marrow Transplant. 2018 Feb; 24: 337-342.
Naeimi Kararoudi M, Hejazi SS, Elmas E, Hellström M, Naeimi Kararoudi M, Padma AM, Lee D, Dolatshad H. Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Gene Editing Technique in Xenotransplantation. Front Immunol. 2018; 9: 1711.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Correction: Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0197008.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0191358.
Streltsova MA, Erokhina SA, Kanevskiy LM, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Analysis of NK cell clones obtained using interleukin-2 and gene-modified K562 cells revealed the ability of "senescent" NK cells to lose CD57 expression and start expressing NKG2A. PLoS One. 2018; 13: e0208469.
View More Publications
Research
Lab(s)
Center for Childhood Cancer
Publications
de Souza Fernandez Pereira M, Carr DR, Gatti-Mays ME, Olsen MR, Setty BA, Shahwan KT, Lee DA. Natural Killer Cell Recognition and Control of Epithelial Cancers. Cancer J. 2022 Jul-Aug 01; 28: 263-269.
Fair SR, Schwind W, Julian D, Biel A, Guo G, Rutherford R, Ramadesikan S, Westfall J, Miller KE, Kararoudi MN, Hickey SE, Mosher TM, McBride KL, Neinast R, Fitch J, Lee D, White P, Wilson RK, Bedrosian TA, Koboldt DC, Hester ME. Cerebral organoids containing an AUTS2 missense variant model microcephaly. Brain. 2022 Jul 8;
Naeimi Kararoudi M, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, de Souza Fernandes Pereira M, Sezgin Y, Devine RD, Lyberger JM, Behbehani GK, Chakravarti N, Moriarity BS, Meyer K, Lee DA. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Rep Methods. 2022 Jun 20; 2: 100236.
Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo XM, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat SA, Rogers KA, Lee D, Muthusamy N, Byrd JC. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Adv. 2022 Apr 29;
Scorza BM, Mahachi KG, Cox AD, Toepp AJ, Pessoa-Pereira D, Tyrrell P, Buch J, Foltz JA, Lee D, Petersen CA. Role of NK-Like CD8+ T Cells during Asymptomatic Borrelia burgdorferi Infection. Infect Immun. 2022 Apr 13; e0055521.
Chu Y, Lamb M, Cairo MS, Lee DA. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Curr Treat Options Oncol. 2022 Mar; 23: 381-403.
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 Jan; 36: 155-164.
Naeimi Kararoudi M, Alsudayri A, Hill CL, Elmas E, Sezgin Y, Thakkar A, Hester ME, Malleske DT, Lee DA, Neal ML, Perry MR, Harvilchuck JA, Reynolds SD. Assessment of Beta-2 Microglobulin Gene Edited Airway Epithelial Stem Cells as a treatment for Sulfur Mustard Inhalation. Front Genome Ed. 2022; 4: 781531.
de Souza Fernandes Pereira M, Thakkar A, Lee DA. Non-invasive fluorescence imaging for tracking immune cells in preclinical models of immunotherapy. Methods Cell Biol. 2022; 167: 163-170.
Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, Lee DA, Naeimi Kararoudi M. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. Front Oncol. 2022; 12: 834002.
Silla L, Valim V, Pezzi A, da Silva M, Wilke I, Nobrega J, Vargas A, Amorin B, Correa B, Zambonato B, Scherer F, Merzoni J, Sekine L, Huls H, Cooper LJ, Paz A, Lee DA. Adoptive immunotherapy with double-bright (CD56bright /CD16bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study. Br J Haematol. 2021 Dec; 195: 710-721.
Trikha P, Moseman JE, Thakkar A, Campbell AR, Elmas E, Foltz JA, Chakravarti N, Fitch JR, Mardis ER, Lee DA. Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function. Blood Adv. 2021 Nov 23; 5: 4605-4618.
Rangarajan HG, Pereira MSF, Brazauskas R, St Martin A, Kussman A, Elmas E, Verneris MR, Gadalla SM, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Lee DA. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. Transplant Cell Ther. 2021 Nov; 27: 926.e1-926.e10.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021 Aug 14; 11: 146.
Chu Y, Nayyar G, Jiang S, Rosenblum JM, Soon-Shiong P, Safrit JT, Lee DA, Cairo MS. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. J Immunother Cancer. 2021 Jul; 9:
Wright M, Rangarajan H, Abu-Arja R, Auletta JJ, Lee D, Polishchuk V, Pai V, Taylor K, Bajwa RPS. Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2021 May 20; e14041.
Lamb MG, Rangarajan HG, Tullius BP, Lee DA. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res Ther. 2021 Mar 25; 12: 211.
Kisseberth WC, Lee DA. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma. Front Vet Sci. 2021; 8: 672361.
Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.
Chu Y, Awasthi A, Lee S, Edani D, Yin C, Hochberg J, Shah T, Chung TH, Ayello J, van de Ven C, Klein C, Lee D, Cairo MS. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget. 2020 Aug 11; 11: 3035-3047.
Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 2020 Aug 17; 22: 1214-1225.
Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. Cytotherapy. 2020 Jul; 22: 369-376.
Moseman JE, Foltz JA, Sorathia K, Heipertz EL, Lee DA. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells. Cytotherapy. 2020 Jun; 22: 322-328.
Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, Haymaker C, Bernatchez C, Lee DA, Watowich SS, Yee C. Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunol Res. 2020 Jun; 8: 794-805.
Verneris MR, Miller JS, Hsu KC, Wang T, Sees JA, Paczesny S, Rangarajan H, Lee DA, Spellman SR, Lee SJ. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020 Apr 14; 4: 1350-1356.
Judge SJ, Yanagisawa M, Sturgill IR, Bateni SB, Gingrich AA, Foltz JA, Lee DA, Modiano JF, Monjazeb AM, Culp WTN, Rebhun RB, Murphy WJ, Kent MS, Canter RJ. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS One. 2020; 15: e0224775.
Trikha P, Lee DA. The role of AhR in transcriptional regulation of immune cell development and function. Biochim Biophys Acta Rev Cancer. 2020 Jan; 1873: 188335.
Tullius BP, Setty BA, Lee DA. Natural Killer Cell Immunotherapy for Osteosarcoma. Adv Exp Med Biol. 2020; 1257: 141-154.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Vahidy FS, Haque ME, Rahbar MH, Zhu H, Rowan P, Aisiku IP, Lee DA, Juneja HS, Alderman S, Barreto AD, Suarez JI, Bambhroliya A, Hasan KM, Kassam MR, Aronowski J, Gee A, Cox CS Jr, Grotta JC, Savitz SI. Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. Stem Cells. 2019 Nov; 37: 1481-1491.
Ojo EO, Sharma AA, Liu R, Moreton S, Checkley-Luttge MA, Gupta K, Lee G, Lee DA, Otegbeye F, Sekaly RP, de Lima M, Wald DN. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep. 2019 Oct 17; 9: 14916.
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Lee DA. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. Immunol Rev. 2019 Jul; 290: 85-99.
Ray AK, Somanchi SS, Dastgheyb N, Lopez AA, Cobanoglu ZE, Geier B, Lee DA. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatr Blood Cancer. 2019 Jul 15; e27783.
Lamb MG, Lee DA. Donor-Derived Cytokine-Induced Killer Cells after Nonmyeloablative Transplant for Myeloid Neoplasms. Biol Blood Marrow Transplant. 2019 May 23;
Lamb MG, Lee DA. Donor Lymphocyte Infusions versus Cytokine-Induced Killer Cells for Hematologic Malignancies after Transplantation. Biol Blood Marrow Transplant. 2019 May 22;
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 409.
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 395-407.
Streltsova MA, Erokhina SA, Kanevskiy LM, Grechikhina MV, Kobyzeva PA, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-? Production, and Lifespan. Int J Mol Sci. 2019 Jan 21; 20:
Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, Roméro H, Selleri S, Béland K, Guiot M, Tremblay-Laganière C, Dicaire R, Barreiro L, Lee DA, Verhoeyen E, Haddad E. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector. Front Immunol. 2019; 10: 2873.
Schafer JR, Salzillo TC, Chakravarti N, Kararoudi MN, Trikha P, Foltz JA, Wang R, Li S, Lee DA. Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. J Allergy Clin Immunol. 2019 Jan; 143: 346-358.e6.
Foltz JA, Moseman JE, Thakkar A, Chakravarti N, Lee DA. TGFß Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion. Cancers (Basel). 2018 Nov 5; 10:
Wedekind MF, Haworth KB, Arnold M, Stanek JR, Lee D, Cripe TP. Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatr Blood Cancer. 2018 Nov; 65: e27313.
Adelman ZN, Albritton LM, Boris-Lawrie K, Buchmeier MJ, Cannon P, Cho M, DiGiusto D, Donahue JK, Federoff HJ, Hammarskjold ML, Hardison AD, Hearing P, Lee B, Lee DA, Porteus MH, Ross LF, Ross SR, Wooley DP, Zoloth L. Protect NIH's DNA advisory committee. Science. 2018 Oct 26; 362: 409-410.
Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, Caligiuri MA, Mishra A. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Adv. 2018 Aug 14; 2: 1818-1827.
Poznanski SM, Nham T, Chew MV, Lee AJ, Hammill JA, Fan IY, Butcher M, Bramson JL, Lee DA, Hirte HW, Ashkar AA. Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. Cancer Immunol Res. 2018 Jul 17;
Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;
Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant. 2018 May; 24: 895-908.
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018 Apr 19; 9: 1567.
Nham T, Poznanski SM, Fan IY, Shenouda MM, Chew MV, Lee AJ, Vahedi F, Karimi Y, Butcher M, Lee DA, Hirte H, Ashkar AA. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunol Immunother. 2018 Apr; 67: 575-587.
Nham T, Poznanski SM, Fan IY, Vahedi F, Shenouda MM, Lee AJ, Chew MV, Hogg RT, Lee DA, Ashkar AA. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. J Immunother. 2018 Feb/Mar; 41: 64-72.
Rangarajan HG, Stanek JR, Abu-Arja R, Bajwa RPS, Auletta JJ, Lee DA, O'Brien SH, Kumar R. Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. Biol Blood Marrow Transplant. 2018 Feb; 24: 337-342.
Naeimi Kararoudi M, Hejazi SS, Elmas E, Hellström M, Naeimi Kararoudi M, Padma AM, Lee D, Dolatshad H. Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Gene Editing Technique in Xenotransplantation. Front Immunol. 2018; 9: 1711.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Correction: Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0197008.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0191358.
Streltsova MA, Erokhina SA, Kanevskiy LM, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Analysis of NK cell clones obtained using interleukin-2 and gene-modified K562 cells revealed the ability of "senescent" NK cells to lose CD57 expression and start expressing NKG2A. PLoS One. 2018; 13: e0208469.
View More Publications
Lab(s)
Center for Childhood Cancer
Publications
de Souza Fernandez Pereira M, Carr DR, Gatti-Mays ME, Olsen MR, Setty BA, Shahwan KT, Lee DA. Natural Killer Cell Recognition and Control of Epithelial Cancers. Cancer J. 2022 Jul-Aug 01; 28: 263-269.
Fair SR, Schwind W, Julian D, Biel A, Guo G, Rutherford R, Ramadesikan S, Westfall J, Miller KE, Kararoudi MN, Hickey SE, Mosher TM, McBride KL, Neinast R, Fitch J, Lee D, White P, Wilson RK, Bedrosian TA, Koboldt DC, Hester ME. Cerebral organoids containing an AUTS2 missense variant model microcephaly. Brain. 2022 Jul 8;
Naeimi Kararoudi M, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, de Souza Fernandes Pereira M, Sezgin Y, Devine RD, Lyberger JM, Behbehani GK, Chakravarti N, Moriarity BS, Meyer K, Lee DA. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Rep Methods. 2022 Jun 20; 2: 100236.
Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo XM, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat SA, Rogers KA, Lee D, Muthusamy N, Byrd JC. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Adv. 2022 Apr 29;
Scorza BM, Mahachi KG, Cox AD, Toepp AJ, Pessoa-Pereira D, Tyrrell P, Buch J, Foltz JA, Lee D, Petersen CA. Role of NK-Like CD8+ T Cells during Asymptomatic Borrelia burgdorferi Infection. Infect Immun. 2022 Apr 13; e0055521.
Chu Y, Lamb M, Cairo MS, Lee DA. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Curr Treat Options Oncol. 2022 Mar; 23: 381-403.
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 Jan; 36: 155-164.
Naeimi Kararoudi M, Alsudayri A, Hill CL, Elmas E, Sezgin Y, Thakkar A, Hester ME, Malleske DT, Lee DA, Neal ML, Perry MR, Harvilchuck JA, Reynolds SD. Assessment of Beta-2 Microglobulin Gene Edited Airway Epithelial Stem Cells as a treatment for Sulfur Mustard Inhalation. Front Genome Ed. 2022; 4: 781531.
de Souza Fernandes Pereira M, Thakkar A, Lee DA. Non-invasive fluorescence imaging for tracking immune cells in preclinical models of immunotherapy. Methods Cell Biol. 2022; 167: 163-170.
Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, Lee DA, Naeimi Kararoudi M. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. Front Oncol. 2022; 12: 834002.
Silla L, Valim V, Pezzi A, da Silva M, Wilke I, Nobrega J, Vargas A, Amorin B, Correa B, Zambonato B, Scherer F, Merzoni J, Sekine L, Huls H, Cooper LJ, Paz A, Lee DA. Adoptive immunotherapy with double-bright (CD56bright /CD16bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study. Br J Haematol. 2021 Dec; 195: 710-721.
Trikha P, Moseman JE, Thakkar A, Campbell AR, Elmas E, Foltz JA, Chakravarti N, Fitch JR, Mardis ER, Lee DA. Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function. Blood Adv. 2021 Nov 23; 5: 4605-4618.
Rangarajan HG, Pereira MSF, Brazauskas R, St Martin A, Kussman A, Elmas E, Verneris MR, Gadalla SM, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Lee DA. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. Transplant Cell Ther. 2021 Nov; 27: 926.e1-926.e10.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021 Aug 14; 11: 146.
Chu Y, Nayyar G, Jiang S, Rosenblum JM, Soon-Shiong P, Safrit JT, Lee DA, Cairo MS. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. J Immunother Cancer. 2021 Jul; 9:
Wright M, Rangarajan H, Abu-Arja R, Auletta JJ, Lee D, Polishchuk V, Pai V, Taylor K, Bajwa RPS. Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2021 May 20; e14041.
Lamb MG, Rangarajan HG, Tullius BP, Lee DA. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res Ther. 2021 Mar 25; 12: 211.
Kisseberth WC, Lee DA. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma. Front Vet Sci. 2021; 8: 672361.
Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.
Chu Y, Awasthi A, Lee S, Edani D, Yin C, Hochberg J, Shah T, Chung TH, Ayello J, van de Ven C, Klein C, Lee D, Cairo MS. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget. 2020 Aug 11; 11: 3035-3047.
Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 2020 Aug 17; 22: 1214-1225.
Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. Cytotherapy. 2020 Jul; 22: 369-376.
Moseman JE, Foltz JA, Sorathia K, Heipertz EL, Lee DA. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells. Cytotherapy. 2020 Jun; 22: 322-328.
Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, Haymaker C, Bernatchez C, Lee DA, Watowich SS, Yee C. Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunol Res. 2020 Jun; 8: 794-805.
Verneris MR, Miller JS, Hsu KC, Wang T, Sees JA, Paczesny S, Rangarajan H, Lee DA, Spellman SR, Lee SJ. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020 Apr 14; 4: 1350-1356.
Judge SJ, Yanagisawa M, Sturgill IR, Bateni SB, Gingrich AA, Foltz JA, Lee DA, Modiano JF, Monjazeb AM, Culp WTN, Rebhun RB, Murphy WJ, Kent MS, Canter RJ. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS One. 2020; 15: e0224775.
Trikha P, Lee DA. The role of AhR in transcriptional regulation of immune cell development and function. Biochim Biophys Acta Rev Cancer. 2020 Jan; 1873: 188335.
Tullius BP, Setty BA, Lee DA. Natural Killer Cell Immunotherapy for Osteosarcoma. Adv Exp Med Biol. 2020; 1257: 141-154.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Vahidy FS, Haque ME, Rahbar MH, Zhu H, Rowan P, Aisiku IP, Lee DA, Juneja HS, Alderman S, Barreto AD, Suarez JI, Bambhroliya A, Hasan KM, Kassam MR, Aronowski J, Gee A, Cox CS Jr, Grotta JC, Savitz SI. Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. Stem Cells. 2019 Nov; 37: 1481-1491.
Ojo EO, Sharma AA, Liu R, Moreton S, Checkley-Luttge MA, Gupta K, Lee G, Lee DA, Otegbeye F, Sekaly RP, de Lima M, Wald DN. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep. 2019 Oct 17; 9: 14916.
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Lee DA. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. Immunol Rev. 2019 Jul; 290: 85-99.
Ray AK, Somanchi SS, Dastgheyb N, Lopez AA, Cobanoglu ZE, Geier B, Lee DA. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatr Blood Cancer. 2019 Jul 15; e27783.
Lamb MG, Lee DA. Donor-Derived Cytokine-Induced Killer Cells after Nonmyeloablative Transplant for Myeloid Neoplasms. Biol Blood Marrow Transplant. 2019 May 23;
Lamb MG, Lee DA. Donor Lymphocyte Infusions versus Cytokine-Induced Killer Cells for Hematologic Malignancies after Transplantation. Biol Blood Marrow Transplant. 2019 May 22;
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 409.
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 395-407.
Streltsova MA, Erokhina SA, Kanevskiy LM, Grechikhina MV, Kobyzeva PA, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-? Production, and Lifespan. Int J Mol Sci. 2019 Jan 21; 20:
Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, Roméro H, Selleri S, Béland K, Guiot M, Tremblay-Laganière C, Dicaire R, Barreiro L, Lee DA, Verhoeyen E, Haddad E. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector. Front Immunol. 2019; 10: 2873.
Schafer JR, Salzillo TC, Chakravarti N, Kararoudi MN, Trikha P, Foltz JA, Wang R, Li S, Lee DA. Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. J Allergy Clin Immunol. 2019 Jan; 143: 346-358.e6.
Foltz JA, Moseman JE, Thakkar A, Chakravarti N, Lee DA. TGFß Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion. Cancers (Basel). 2018 Nov 5; 10:
Wedekind MF, Haworth KB, Arnold M, Stanek JR, Lee D, Cripe TP. Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatr Blood Cancer. 2018 Nov; 65: e27313.
Adelman ZN, Albritton LM, Boris-Lawrie K, Buchmeier MJ, Cannon P, Cho M, DiGiusto D, Donahue JK, Federoff HJ, Hammarskjold ML, Hardison AD, Hearing P, Lee B, Lee DA, Porteus MH, Ross LF, Ross SR, Wooley DP, Zoloth L. Protect NIH's DNA advisory committee. Science. 2018 Oct 26; 362: 409-410.
Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, Caligiuri MA, Mishra A. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Adv. 2018 Aug 14; 2: 1818-1827.
Poznanski SM, Nham T, Chew MV, Lee AJ, Hammill JA, Fan IY, Butcher M, Bramson JL, Lee DA, Hirte HW, Ashkar AA. Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. Cancer Immunol Res. 2018 Jul 17;
Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;
Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant. 2018 May; 24: 895-908.
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018 Apr 19; 9: 1567.
Nham T, Poznanski SM, Fan IY, Shenouda MM, Chew MV, Lee AJ, Vahedi F, Karimi Y, Butcher M, Lee DA, Hirte H, Ashkar AA. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunol Immunother. 2018 Apr; 67: 575-587.
Nham T, Poznanski SM, Fan IY, Vahedi F, Shenouda MM, Lee AJ, Chew MV, Hogg RT, Lee DA, Ashkar AA. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. J Immunother. 2018 Feb/Mar; 41: 64-72.
Rangarajan HG, Stanek JR, Abu-Arja R, Bajwa RPS, Auletta JJ, Lee DA, O'Brien SH, Kumar R. Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. Biol Blood Marrow Transplant. 2018 Feb; 24: 337-342.
Naeimi Kararoudi M, Hejazi SS, Elmas E, Hellström M, Naeimi Kararoudi M, Padma AM, Lee D, Dolatshad H. Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Gene Editing Technique in Xenotransplantation. Front Immunol. 2018; 9: 1711.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Correction: Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0197008.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0191358.
Streltsova MA, Erokhina SA, Kanevskiy LM, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Analysis of NK cell clones obtained using interleukin-2 and gene-modified K562 cells revealed the ability of "senescent" NK cells to lose CD57 expression and start expressing NKG2A. PLoS One. 2018; 13: e0208469.
View More Publications
Lab(s)
Center for Childhood Cancer
de Souza Fernandez Pereira M, Carr DR, Gatti-Mays ME, Olsen MR, Setty BA, Shahwan KT, Lee DA. Natural Killer Cell Recognition and Control of Epithelial Cancers. Cancer J. 2022 Jul-Aug 01; 28: 263-269.
Fair SR, Schwind W, Julian D, Biel A, Guo G, Rutherford R, Ramadesikan S, Westfall J, Miller KE, Kararoudi MN, Hickey SE, Mosher TM, McBride KL, Neinast R, Fitch J, Lee D, White P, Wilson RK, Bedrosian TA, Koboldt DC, Hester ME. Cerebral organoids containing an AUTS2 missense variant model microcephaly. Brain. 2022 Jul 8;
Naeimi Kararoudi M, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, de Souza Fernandes Pereira M, Sezgin Y, Devine RD, Lyberger JM, Behbehani GK, Chakravarti N, Moriarity BS, Meyer K, Lee DA. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Rep Methods. 2022 Jun 20; 2: 100236.
Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo XM, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat SA, Rogers KA, Lee D, Muthusamy N, Byrd JC. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Adv. 2022 Apr 29;
Scorza BM, Mahachi KG, Cox AD, Toepp AJ, Pessoa-Pereira D, Tyrrell P, Buch J, Foltz JA, Lee D, Petersen CA. Role of NK-Like CD8+ T Cells during Asymptomatic Borrelia burgdorferi Infection. Infect Immun. 2022 Apr 13; e0055521.
Chu Y, Lamb M, Cairo MS, Lee DA. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Curr Treat Options Oncol. 2022 Mar; 23: 381-403.
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 Jan; 36: 155-164.
Naeimi Kararoudi M, Alsudayri A, Hill CL, Elmas E, Sezgin Y, Thakkar A, Hester ME, Malleske DT, Lee DA, Neal ML, Perry MR, Harvilchuck JA, Reynolds SD. Assessment of Beta-2 Microglobulin Gene Edited Airway Epithelial Stem Cells as a treatment for Sulfur Mustard Inhalation. Front Genome Ed. 2022; 4: 781531.
de Souza Fernandes Pereira M, Thakkar A, Lee DA. Non-invasive fluorescence imaging for tracking immune cells in preclinical models of immunotherapy. Methods Cell Biol. 2022; 167: 163-170.
Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, Lee DA, Naeimi Kararoudi M. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. Front Oncol. 2022; 12: 834002.
Silla L, Valim V, Pezzi A, da Silva M, Wilke I, Nobrega J, Vargas A, Amorin B, Correa B, Zambonato B, Scherer F, Merzoni J, Sekine L, Huls H, Cooper LJ, Paz A, Lee DA. Adoptive immunotherapy with double-bright (CD56bright /CD16bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study. Br J Haematol. 2021 Dec; 195: 710-721.
Trikha P, Moseman JE, Thakkar A, Campbell AR, Elmas E, Foltz JA, Chakravarti N, Fitch JR, Mardis ER, Lee DA. Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function. Blood Adv. 2021 Nov 23; 5: 4605-4618.
Rangarajan HG, Pereira MSF, Brazauskas R, St Martin A, Kussman A, Elmas E, Verneris MR, Gadalla SM, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Lee DA. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. Transplant Cell Ther. 2021 Nov; 27: 926.e1-926.e10.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021 Aug 14; 11: 146.
Chu Y, Nayyar G, Jiang S, Rosenblum JM, Soon-Shiong P, Safrit JT, Lee DA, Cairo MS. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. J Immunother Cancer. 2021 Jul; 9:
Wright M, Rangarajan H, Abu-Arja R, Auletta JJ, Lee D, Polishchuk V, Pai V, Taylor K, Bajwa RPS. Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2021 May 20; e14041.
Lamb MG, Rangarajan HG, Tullius BP, Lee DA. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res Ther. 2021 Mar 25; 12: 211.
Kisseberth WC, Lee DA. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma. Front Vet Sci. 2021; 8: 672361.
Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.
Chu Y, Awasthi A, Lee S, Edani D, Yin C, Hochberg J, Shah T, Chung TH, Ayello J, van de Ven C, Klein C, Lee D, Cairo MS. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget. 2020 Aug 11; 11: 3035-3047.
Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 2020 Aug 17; 22: 1214-1225.
Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. Cytotherapy. 2020 Jul; 22: 369-376.
Moseman JE, Foltz JA, Sorathia K, Heipertz EL, Lee DA. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells. Cytotherapy. 2020 Jun; 22: 322-328.
Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, Haymaker C, Bernatchez C, Lee DA, Watowich SS, Yee C. Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunol Res. 2020 Jun; 8: 794-805.
Verneris MR, Miller JS, Hsu KC, Wang T, Sees JA, Paczesny S, Rangarajan H, Lee DA, Spellman SR, Lee SJ. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020 Apr 14; 4: 1350-1356.
Judge SJ, Yanagisawa M, Sturgill IR, Bateni SB, Gingrich AA, Foltz JA, Lee DA, Modiano JF, Monjazeb AM, Culp WTN, Rebhun RB, Murphy WJ, Kent MS, Canter RJ. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS One. 2020; 15: e0224775.
Trikha P, Lee DA. The role of AhR in transcriptional regulation of immune cell development and function. Biochim Biophys Acta Rev Cancer. 2020 Jan; 1873: 188335.
Tullius BP, Setty BA, Lee DA. Natural Killer Cell Immunotherapy for Osteosarcoma. Adv Exp Med Biol. 2020; 1257: 141-154.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Vahidy FS, Haque ME, Rahbar MH, Zhu H, Rowan P, Aisiku IP, Lee DA, Juneja HS, Alderman S, Barreto AD, Suarez JI, Bambhroliya A, Hasan KM, Kassam MR, Aronowski J, Gee A, Cox CS Jr, Grotta JC, Savitz SI. Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. Stem Cells. 2019 Nov; 37: 1481-1491.
Ojo EO, Sharma AA, Liu R, Moreton S, Checkley-Luttge MA, Gupta K, Lee G, Lee DA, Otegbeye F, Sekaly RP, de Lima M, Wald DN. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep. 2019 Oct 17; 9: 14916.
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Lee DA. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. Immunol Rev. 2019 Jul; 290: 85-99.
Ray AK, Somanchi SS, Dastgheyb N, Lopez AA, Cobanoglu ZE, Geier B, Lee DA. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatr Blood Cancer. 2019 Jul 15; e27783.
Lamb MG, Lee DA. Donor-Derived Cytokine-Induced Killer Cells after Nonmyeloablative Transplant for Myeloid Neoplasms. Biol Blood Marrow Transplant. 2019 May 23;
Lamb MG, Lee DA. Donor Lymphocyte Infusions versus Cytokine-Induced Killer Cells for Hematologic Malignancies after Transplantation. Biol Blood Marrow Transplant. 2019 May 22;
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 409.
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 395-407.
Streltsova MA, Erokhina SA, Kanevskiy LM, Grechikhina MV, Kobyzeva PA, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-? Production, and Lifespan. Int J Mol Sci. 2019 Jan 21; 20:
Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, Roméro H, Selleri S, Béland K, Guiot M, Tremblay-Laganière C, Dicaire R, Barreiro L, Lee DA, Verhoeyen E, Haddad E. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector. Front Immunol. 2019; 10: 2873.
Schafer JR, Salzillo TC, Chakravarti N, Kararoudi MN, Trikha P, Foltz JA, Wang R, Li S, Lee DA. Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. J Allergy Clin Immunol. 2019 Jan; 143: 346-358.e6.
Foltz JA, Moseman JE, Thakkar A, Chakravarti N, Lee DA. TGFß Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion. Cancers (Basel). 2018 Nov 5; 10:
Wedekind MF, Haworth KB, Arnold M, Stanek JR, Lee D, Cripe TP. Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatr Blood Cancer. 2018 Nov; 65: e27313.
Adelman ZN, Albritton LM, Boris-Lawrie K, Buchmeier MJ, Cannon P, Cho M, DiGiusto D, Donahue JK, Federoff HJ, Hammarskjold ML, Hardison AD, Hearing P, Lee B, Lee DA, Porteus MH, Ross LF, Ross SR, Wooley DP, Zoloth L. Protect NIH's DNA advisory committee. Science. 2018 Oct 26; 362: 409-410.
Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, Caligiuri MA, Mishra A. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Adv. 2018 Aug 14; 2: 1818-1827.
Poznanski SM, Nham T, Chew MV, Lee AJ, Hammill JA, Fan IY, Butcher M, Bramson JL, Lee DA, Hirte HW, Ashkar AA. Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. Cancer Immunol Res. 2018 Jul 17;
Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;
Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant. 2018 May; 24: 895-908.
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018 Apr 19; 9: 1567.
Nham T, Poznanski SM, Fan IY, Shenouda MM, Chew MV, Lee AJ, Vahedi F, Karimi Y, Butcher M, Lee DA, Hirte H, Ashkar AA. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunol Immunother. 2018 Apr; 67: 575-587.
Nham T, Poznanski SM, Fan IY, Vahedi F, Shenouda MM, Lee AJ, Chew MV, Hogg RT, Lee DA, Ashkar AA. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. J Immunother. 2018 Feb/Mar; 41: 64-72.
Rangarajan HG, Stanek JR, Abu-Arja R, Bajwa RPS, Auletta JJ, Lee DA, O'Brien SH, Kumar R. Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. Biol Blood Marrow Transplant. 2018 Feb; 24: 337-342.
Naeimi Kararoudi M, Hejazi SS, Elmas E, Hellström M, Naeimi Kararoudi M, Padma AM, Lee D, Dolatshad H. Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Gene Editing Technique in Xenotransplantation. Front Immunol. 2018; 9: 1711.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Correction: Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0197008.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0191358.
Streltsova MA, Erokhina SA, Kanevskiy LM, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Analysis of NK cell clones obtained using interleukin-2 and gene-modified K562 cells revealed the ability of "senescent" NK cells to lose CD57 expression and start expressing NKG2A. PLoS One. 2018; 13: e0208469.
View More Publications
Lab(s)
Center for Childhood Cancer
Center for Childhood Cancer
de Souza Fernandez Pereira M, Carr DR, Gatti-Mays ME, Olsen MR, Setty BA, Shahwan KT, Lee DA. Natural Killer Cell Recognition and Control of Epithelial Cancers. Cancer J. 2022 Jul-Aug 01; 28: 263-269.
Fair SR, Schwind W, Julian D, Biel A, Guo G, Rutherford R, Ramadesikan S, Westfall J, Miller KE, Kararoudi MN, Hickey SE, Mosher TM, McBride KL, Neinast R, Fitch J, Lee D, White P, Wilson RK, Bedrosian TA, Koboldt DC, Hester ME. Cerebral organoids containing an AUTS2 missense variant model microcephaly. Brain. 2022 Jul 8;
Naeimi Kararoudi M, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, de Souza Fernandes Pereira M, Sezgin Y, Devine RD, Lyberger JM, Behbehani GK, Chakravarti N, Moriarity BS, Meyer K, Lee DA. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Rep Methods. 2022 Jun 20; 2: 100236.
Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo XM, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat SA, Rogers KA, Lee D, Muthusamy N, Byrd JC. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Adv. 2022 Apr 29;
Scorza BM, Mahachi KG, Cox AD, Toepp AJ, Pessoa-Pereira D, Tyrrell P, Buch J, Foltz JA, Lee D, Petersen CA. Role of NK-Like CD8+ T Cells during Asymptomatic Borrelia burgdorferi Infection. Infect Immun. 2022 Apr 13; e0055521.
Chu Y, Lamb M, Cairo MS, Lee DA. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Curr Treat Options Oncol. 2022 Mar; 23: 381-403.
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 Jan; 36: 155-164.
Naeimi Kararoudi M, Alsudayri A, Hill CL, Elmas E, Sezgin Y, Thakkar A, Hester ME, Malleske DT, Lee DA, Neal ML, Perry MR, Harvilchuck JA, Reynolds SD. Assessment of Beta-2 Microglobulin Gene Edited Airway Epithelial Stem Cells as a treatment for Sulfur Mustard Inhalation. Front Genome Ed. 2022; 4: 781531.
de Souza Fernandes Pereira M, Thakkar A, Lee DA. Non-invasive fluorescence imaging for tracking immune cells in preclinical models of immunotherapy. Methods Cell Biol. 2022; 167: 163-170.
Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, Lee DA, Naeimi Kararoudi M. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. Front Oncol. 2022; 12: 834002.
Silla L, Valim V, Pezzi A, da Silva M, Wilke I, Nobrega J, Vargas A, Amorin B, Correa B, Zambonato B, Scherer F, Merzoni J, Sekine L, Huls H, Cooper LJ, Paz A, Lee DA. Adoptive immunotherapy with double-bright (CD56bright /CD16bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study. Br J Haematol. 2021 Dec; 195: 710-721.
Trikha P, Moseman JE, Thakkar A, Campbell AR, Elmas E, Foltz JA, Chakravarti N, Fitch JR, Mardis ER, Lee DA. Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function. Blood Adv. 2021 Nov 23; 5: 4605-4618.
Rangarajan HG, Pereira MSF, Brazauskas R, St Martin A, Kussman A, Elmas E, Verneris MR, Gadalla SM, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Lee DA. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. Transplant Cell Ther. 2021 Nov; 27: 926.e1-926.e10.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021 Aug 14; 11: 146.
Chu Y, Nayyar G, Jiang S, Rosenblum JM, Soon-Shiong P, Safrit JT, Lee DA, Cairo MS. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. J Immunother Cancer. 2021 Jul; 9:
Wright M, Rangarajan H, Abu-Arja R, Auletta JJ, Lee D, Polishchuk V, Pai V, Taylor K, Bajwa RPS. Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2021 May 20; e14041.
Lamb MG, Rangarajan HG, Tullius BP, Lee DA. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res Ther. 2021 Mar 25; 12: 211.
Kisseberth WC, Lee DA. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma. Front Vet Sci. 2021; 8: 672361.
Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.
Chu Y, Awasthi A, Lee S, Edani D, Yin C, Hochberg J, Shah T, Chung TH, Ayello J, van de Ven C, Klein C, Lee D, Cairo MS. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget. 2020 Aug 11; 11: 3035-3047.
Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 2020 Aug 17; 22: 1214-1225.
Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. Cytotherapy. 2020 Jul; 22: 369-376.
Moseman JE, Foltz JA, Sorathia K, Heipertz EL, Lee DA. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells. Cytotherapy. 2020 Jun; 22: 322-328.
Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, Haymaker C, Bernatchez C, Lee DA, Watowich SS, Yee C. Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunol Res. 2020 Jun; 8: 794-805.
Verneris MR, Miller JS, Hsu KC, Wang T, Sees JA, Paczesny S, Rangarajan H, Lee DA, Spellman SR, Lee SJ. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020 Apr 14; 4: 1350-1356.
Judge SJ, Yanagisawa M, Sturgill IR, Bateni SB, Gingrich AA, Foltz JA, Lee DA, Modiano JF, Monjazeb AM, Culp WTN, Rebhun RB, Murphy WJ, Kent MS, Canter RJ. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS One. 2020; 15: e0224775.
Trikha P, Lee DA. The role of AhR in transcriptional regulation of immune cell development and function. Biochim Biophys Acta Rev Cancer. 2020 Jan; 1873: 188335.
Tullius BP, Setty BA, Lee DA. Natural Killer Cell Immunotherapy for Osteosarcoma. Adv Exp Med Biol. 2020; 1257: 141-154.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Vahidy FS, Haque ME, Rahbar MH, Zhu H, Rowan P, Aisiku IP, Lee DA, Juneja HS, Alderman S, Barreto AD, Suarez JI, Bambhroliya A, Hasan KM, Kassam MR, Aronowski J, Gee A, Cox CS Jr, Grotta JC, Savitz SI. Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. Stem Cells. 2019 Nov; 37: 1481-1491.
Ojo EO, Sharma AA, Liu R, Moreton S, Checkley-Luttge MA, Gupta K, Lee G, Lee DA, Otegbeye F, Sekaly RP, de Lima M, Wald DN. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep. 2019 Oct 17; 9: 14916.
Auletta JJ, Sánchez PJ, Meyer EK, O’Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Lee DA. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. Immunol Rev. 2019 Jul; 290: 85-99.
Ray AK, Somanchi SS, Dastgheyb N, Lopez AA, Cobanoglu ZE, Geier B, Lee DA. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatr Blood Cancer. 2019 Jul 15; e27783.
Lamb MG, Lee DA. Donor-Derived Cytokine-Induced Killer Cells after Nonmyeloablative Transplant for Myeloid Neoplasms. Biol Blood Marrow Transplant. 2019 May 23;
Lamb MG, Lee DA. Donor Lymphocyte Infusions versus Cytokine-Induced Killer Cells for Hematologic Malignancies after Transplantation. Biol Blood Marrow Transplant. 2019 May 22;
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 409.
Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol. 2019 May; 142: 395-407.
Streltsova MA, Erokhina SA, Kanevskiy LM, Grechikhina MV, Kobyzeva PA, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-? Production, and Lifespan. Int J Mol Sci. 2019 Jan 21; 20:
Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, Roméro H, Selleri S, Béland K, Guiot M, Tremblay-Laganière C, Dicaire R, Barreiro L, Lee DA, Verhoeyen E, Haddad E. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector. Front Immunol. 2019; 10: 2873.
Schafer JR, Salzillo TC, Chakravarti N, Kararoudi MN, Trikha P, Foltz JA, Wang R, Li S, Lee DA. Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. J Allergy Clin Immunol. 2019 Jan; 143: 346-358.e6.
Foltz JA, Moseman JE, Thakkar A, Chakravarti N, Lee DA. TGFß Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion. Cancers (Basel). 2018 Nov 5; 10:
Wedekind MF, Haworth KB, Arnold M, Stanek JR, Lee D, Cripe TP. Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatr Blood Cancer. 2018 Nov; 65: e27313.
Adelman ZN, Albritton LM, Boris-Lawrie K, Buchmeier MJ, Cannon P, Cho M, DiGiusto D, Donahue JK, Federoff HJ, Hammarskjold ML, Hardison AD, Hearing P, Lee B, Lee DA, Porteus MH, Ross LF, Ross SR, Wooley DP, Zoloth L. Protect NIH’s DNA advisory committee. Science. 2018 Oct 26; 362: 409-410.
Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, Caligiuri MA, Mishra A. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Adv. 2018 Aug 14; 2: 1818-1827.
Poznanski SM, Nham T, Chew MV, Lee AJ, Hammill JA, Fan IY, Butcher M, Bramson JL, Lee DA, Hirte HW, Ashkar AA. Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. Cancer Immunol Res. 2018 Jul 17;
Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;
Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant. 2018 May; 24: 895-908.
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018 Apr 19; 9: 1567.
Nham T, Poznanski SM, Fan IY, Shenouda MM, Chew MV, Lee AJ, Vahedi F, Karimi Y, Butcher M, Lee DA, Hirte H, Ashkar AA. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunol Immunother. 2018 Apr; 67: 575-587.
Nham T, Poznanski SM, Fan IY, Vahedi F, Shenouda MM, Lee AJ, Chew MV, Hogg RT, Lee DA, Ashkar AA. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. J Immunother. 2018 Feb/Mar; 41: 64-72.
Rangarajan HG, Stanek JR, Abu-Arja R, Bajwa RPS, Auletta JJ, Lee DA, O’Brien SH, Kumar R. Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. Biol Blood Marrow Transplant. 2018 Feb; 24: 337-342.
Naeimi Kararoudi M, Hejazi SS, Elmas E, Hellström M, Naeimi Kararoudi M, Padma AM, Lee D, Dolatshad H. Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Gene Editing Technique in Xenotransplantation. Front Immunol. 2018; 9: 1711.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Correction: Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0197008.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13: e0191358.
Streltsova MA, Erokhina SA, Kanevskiy LM, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI. Analysis of NK cell clones obtained using interleukin-2 and gene-modified K562 cells revealed the ability of “senescent” NK cells to lose CD57 expression and start expressing NKG2A. PLoS One. 2018; 13: e0208469.
Education
Date of Appointment at Nationwide Children’s Hospital: 07/01/2016
Board Certifications
Pediatric Hematology Oncology
Fellowship
Texas Children’s Hospital
Date Completed: 06/30/2003
Residency
Loma Linda Children’s Hospital
Date Completed: 06/30/1999
Medical School
Loma Linda University School of Medicine
Date Completed: 06/01/1996
Education
Date of Appointment at Nationwide Children’s Hospital: 07/01/2016
Board Certifications
Pediatric Hematology Oncology
Fellowship
Texas Children’s Hospital
Date Completed: 06/30/2003
Residency
Loma Linda Children’s Hospital
Date Completed: 06/30/1999
Medical School
Loma Linda University School of Medicine
Date Completed: 06/01/1996
Education
Date of Appointment at Nationwide Children’s Hospital: 07/01/2016
Board Certifications
Pediatric Hematology Oncology
Fellowship
Texas Children’s Hospital
Date Completed: 06/30/2003
Residency
Loma Linda Children’s Hospital
Date Completed: 06/30/1999
Medical School
Loma Linda University School of Medicine
Date Completed: 06/01/1996
Date of Appointment at Nationwide Children’s Hospital: 07/01/2016
Board Certifications
Pediatric Hematology Oncology
Fellowship
Texas Children’s Hospital
Date Completed: 06/30/2003
Residency
Loma Linda Children’s Hospital
Date Completed: 06/30/1999
Medical School
Loma Linda University School of Medicine
Date Completed: 06/01/1996
Date of Appointment at Nationwide Children’s Hospital: 07/01/2016
Board Certifications
Pediatric Hematology Oncology
Fellowship
Texas Children’s Hospital
Date Completed: 06/30/2003
Residency
Loma Linda Children’s Hospital
Date Completed: 06/30/1999
Medical School
Loma Linda University School of Medicine
Date Completed: 06/01/1996
- Pediatric Hematology Oncology
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
- Call us at:
- (614) 722-3550
- Fax us at:
- (614) 722-3369
- Hematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
